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Sympathomimetic agents have a poor history of long-term success in the treatment of obesity. From earlier experiences with
amphetamine and its analogs, to more recent drugs with direct eﬀects on adrenergic receptors or indirect eﬀects from release of
catecholamines or inhibition of reuptake, cardiovascular toxicity (strokes and cardiac arrhythmias) has been the major concern.
These concerns also extended to food supplements containing ephedra alkaloids and may require consideration for current
supplements containing the sympathomimetic drug, synephrine.
Sibutramine is the most recent drug with sympathomimetic
activity that has been recognized by regulatory agencies as
having cardiovascular adverse eﬀects that may outweigh its
potentialvalueasaweightlossdrug.Sibutramineismarketed
in Europe under several trade names, including Reductil,
Reduxade, Ectiva, Sibutral, Zelium, and others. Meridia is
the only brand name in the United States. The European
Medicines Agency took deﬁnitive action on January 21, 2010
inadvisingagainstthecontinuedprescribingofthedrug,and
Abbott Laboratories suspended sales of the drug in Europe
[1]. This action was prompted by a preliminary evaluation
of results from the Sibutramine Cardiovascular OUTcome
(SCOUT) trial reported by the United States FDA [2]. The
FDA has not imposed a ban on the drug but has obtained
a change in the boxed warning label to contraindicate its
use in patients with a history of cardiovascular disease and
in all individuals over 65 years of age (updated warning,
April 15, 2010). These regulatory actions were prompted
by an early review of the SCOUT trial [3] that revealed
an incidence of cardiovascular events of 11.4% in patients
receiving sibutramine compared to 10% in those receiving
placebo. This was an unexpected ﬁnding; the hypothesis in
the design of the study was that an anticipated weight loss
from the use of sibutramine would be associated with a
reduction in the incidence of cardiovascular events when
compared to that observed in patients receiving the placebo
treatment [3].
Sibutramine was not developed as a sympathomimetic
drug. In early studies, it was ﬁrst evaluated for its poten-
tial as an antidepressant medication, and its behavioral
eﬀects were apparently explained by its inhibition of both
5-hydroxytryptamine (5-HT) and norepinephrine reuptake
in the central nervous system (CNS) [4, 5]. The inhibition
of monoamine uptake is produced almost completely by
two metabolites of sibutramine [5]. The hypophagic eﬀect
of sibutramine was recognized later, and this became the
focus of its development as an antiobesity drug [6–8]. Its
sympathomimetic eﬀects (an increase in heart rate and
blood pressure), which are of concern in relation to the
observed increase in adverse cardiovascular events, would
appear to be primarily related to a peripheral inhibition
of norepinephrine reuptake and interrelationships with
sympathetic outﬂow from the CNS [9, 10]. The increases
in heart rate and blood pressure would be expected to
follow from inhibition of norepinephrine reuptake by
sibutramine (mostly its metabolites) at sympathetic nerve
endings in the heart and blood vessels. This eﬀect would
be magniﬁed during physical activity or other conditions
of stress that would increase sympathetic nerve activity and
norepinephrine overﬂow in the periphery. These increases2 Journal of Obesity
in heart rate and blood pressure are seen, despite the fact
that sibutramine is known to blunt the intensity of central
sympathetic outﬂow by virtue of α2-adrenergic suppression
of sympathetic activity in the CNS. The locus of this action
is considered to include α2-adrenergic receptors in the lower
portion of the brain stem (medulla oblongata) [11]. This
is also the presumed site of action of the antihypertensive
drug, clonidine. The extent to which sympathetic outﬂow
is decreased by this central inhibitory eﬀect of overﬂow
norepinephrine may be limited, because sibutramine has
beenobservedtorapidly(withindays)desensitizecentralα2-
adrenergic receptors in animal studies [12].
Amphetamines, phentermine, and phenyl-propanol-
amine (PPA) are sympathomimetic amines that were once
widely used for the treatment of obesity because of their
anorexic eﬀects [13, 14]. They are all contraindicated for
this use at this time because of their adverse cardiovascular
and/or behavioral proﬁles. They are primarily indirect acting
amines, that is, they release norepinephrine from sympa-
thetic nerve endings. These amines all have an α-methyl
substitution, which results in inhibition of monoamine
oxidase and an intensiﬁcation and prolongation of their
pharmacological eﬀects. In addition, the dextro isomer of
amphetamine, dexamphetamine, is a potent inhibitor of
norepinephrine reuptake, which may be the basis for its
greater potency over the levoisomer [13]. The unregulated
sale of supplements containing ephedra alkaloids is probably
the most recent example of the discontinued use of a
group of sympathomimetic entities for weight loss. These
supplements were banned by the FDA in 2004 because
of their unreasonable risks of cardiovascular toxicity. The
complete ban on ephedra sales was challenged in 2005;
that challenge was overturned on appeal by the FDA, with
conﬁrmation of the ban in 2006. The United States Supreme
Court declined to review a further industry appeal in 2007.
(I have commented previously on the cardiovascular risks of
ephedra alkaloids [15].)
As one of several consultants to the FDA before the
imposition of the ephedra ban [16], I conducted an evalu-
ation of the pharmacology and inherent safety concerns of
ephedra alkaloids. The principal focus in that analysis con-
cerned ephedrine. Although the natural herb, Ephedra sinica
(Ma Huang), contains three sympathomimetic agents in
addition to ephedrine (pseudoephedrine, methylephedrine,
and phenylpropanolamine), ephedrine is the most potent
and is typically present in the highest concentration among
the four alkaloids [17]. The sympathomimetic impact of
ephedrine results from a combination of multiple actions.
Ephedrine is classiﬁed as both a direct and indirect acting
amine. Its indirect eﬀects result primarily from the fact
that it causes a displacement release of norepinephrine
from sympathetic nerve endings. In addition to releas-
ing norepinephrine, ephedrine blocks the reuptake of
norepinephrineintosympatheticnerveterminals.Ephedrine
is also an inhibitor of the degradation of norepinephrine by
monoamine oxidase. Thus, by three mechanisms, ephedrine
magniﬁes the intensity and duration of action of nore-
pinephrine that is released [13, 14, 18]. Obviously, this
entire process is further ampliﬁed during periods of physical
exercise, where sympathetic nerve activity is increased. In
addition to indirect eﬀects of ephedrine, it also has direct
vasoconstrictor (α1-adrenergic), cardiac acceleration and
increased contractility (β1-adrenergic), and bronchodilator
(β2-adrenergic) eﬀects. This triad of eﬀects is similar to that
of epinephrine. The direct eﬀects of ephedrine summate
with its indirect eﬀects to produce its total cardiovascular
impact.
A major negative impact of ephedrine upon the heart
is its ability to induce cardiac arrhythmias. The primary
mechanism involved in this risk is the fact that ephedrine
and all sympathomimetic drugs that activate β1-adrenergic
receptors (either directly or through release, inhibition of
reuptake, or inhibition of metabolism of norepinephrine)
shorten the refractory period of the conducting system of the
heart and cardiac muscle [11]. This is particularly problem-
atic in an individual who is exercising, because the increased
sympathetic outﬂow with exercise augments the release of
norepinephrine, which itself has β1-adrenergic activity. This
adds to the shortening of refractoriness of cardiac cells.
A shortening of the refractory period of myocardial cells
is an essential element in the induction of a re-entrant
arrhythmia, that is, an impulse may now encounter receptive
cells, cells that would ordinarily be refractory and would not
allow for a premature activation. That premature activation
can permit an abnormal route of electrical excitation, that
is, an arrhythmia [19]. In addition, myocardial ischemia
caused by exercise and/or exacerbated by the presence of
coronary artery obstruction also results in a shortening of
the refractory period of myocardial cells [19, 20]. Since the
presence of coronary artery disease may be unrecognized in
many individuals during routine activities, the summation
of drug and stress eﬀects on the electrophysiology of the
heart requires consideration. Recent data presented by the
American Heart Association shows that the incidence of
cardiovascular disease is 39.6 percent in the age group 40
to 59 years (identical for men and women) and 73.6 percent
and 73.1 percent in the age group 60 to 79 years for men and
women, respectively [21].
In addition to the risks of stroke associated with
blood pressure elevations produced by sympathomimetic
drugs, increases in blood pressure may also contribute an
arrhythmogenic potential. With increases in blood pressure,
compensatory baroreceptor-mediated predominance of the
parasympathetic nervous system does result in a slowing of
heart rate in comparison to the eﬀect that would take place
as a result of β1-adrenergic activation alone. Although this
mayreducetheextentofbloodpressureelevation,itdoesnot
reducethearrhythmogenicpotentialoftheelectrophysiolog-
ical processes discussed above. In fact, the participation of
the parasympathetic nervous system to slow heart rate does
sobyreleaseofits mediator, acetylcholine. Acetylcholine also
shortens the refractory period of atrial tissues, which may be
causally related to the induction of atrial ﬁbrillation, atrial
ﬂutter, or paroxysmal supraventricular tachycardia [11].
Thus, direct sympathomimetic stimulation of β1-adrenergic
receptors, indirect eﬀects through released norepinephrine,
ischemia, and compensatory acetylcholine release, may each
be primary or may summate to induce cardiac arrhythmias.Journal of Obesity 3
As a result of the loss of availability of ephedra-cont-
aining products, the sympathomimetic amine, synephrine,
a p p e a r st oh a v eb e c o m ea ni m p o r t a n tf o c u so ft h ef o o d
supplement industry. Synephrine is chemically related to the
well-knownvasopressordrug,phenylephrine;phenylephrine
is the meta-hydroxy-phenyl isomer of synephrine. As with
phenylephrine, synephrine increases blood pressure through
its α1-adrenergic-mediated vasoconstrictor eﬀect [13].
There are a number of supplements currently on the
market that identify synephrine as a major ingredient of
the product. Information about these products is readily
available through searches for synephrine. Various claims are
made as to the value of this constituent for weight loss and
development of physical ﬁtness. Several of these commercial
products contain a fairly well-characterized extract of Citrus
aurantium (bitter orange), which is called “ADVANTRA
Z”. ADVANTRA Z is supplied by Nutratech, Inc. [22]. The
descriptions of patents for ADVANTRA Z indicate that, in
addition to synephrine, it contains three other orally active
sympathomimetic agents, N-methyltyramine, hordenine,
and octopamine [13] .T h eN u t r a t e c hw e b s i t es u g g e s t sa
daily intake of 100 to 120mg of synephrine, in two to three
divided servings.
The potential cardiovascular eﬀects of the doses of
synephrine present in ADVANTRA Z can be placed in
perspective because synephrine is the active ingredient in the
orally active vasopressor drug, oxedrine tartrate. A common
trade name for this preparation in Europe is Sympatol [23].
Oxedrine tartrate is not marketed in the United States.
Sympatol carries the clinical indication for the treatment
of hypotension, that is, to raise blood pressure, with oral
doses of 100 to 150mg, up to three times a day. To compare
doses of synephrine in ADVANTRA Z with clinical doses of
Sympatol, it is necessary to correct for the fact that Sympatol
is the racemic mixture of synephrine (the l-isomer has the
predominant sympathomimetic activity) and that it is the
tartrate salt. (The l-isomer of synephrine is the form in
citrus extracts [24, 25].) Therefore, the molecular weight of
synephrinetartrateis484.5.Ofthis,thel-synephrine content
is 167.2 or 34.5% of the dose.
Thus, the single oral dose range of 100 to 150mg
of Sympatol supplies 34.5 to 51.8mg of l-synephrine. If
3 doses are given per day, the total daily dose would
be 103.5 to 155.4mg of synephrine. This overlaps the
suggested intake for ADVANTRA Z of 100 to 120mg of
synephrine per day. As discussed above, in addition to the
danger of stroke associated with drug-induced increases in
blood pressure, compensatory responses to these increases,
mediated through the parasympathetic nervous system,
may be arrhythmogenic. Also, these concerns would be
expected to be enhanced in conjunction with physical eﬀort.
The National Center for Complementary and Alternative
Medicine, National Institutes of Health, has noted the
potential risks for cardiovascular toxicity from consumption
of extracts of Citrus aurantium [26].
In summary, sympathomimetic agents do not have a
successful record for the treatment of weight loss. They
apparently possess an unreasonable cardiovascular toxic
potential that emerges when the drugs are applied to a
broad spectrum of the population, many of whom may have
unrecognized risk factors.
Disclosure
The author was compensated as a consultant to the US Food
Administrationforevaluationofsympathomimeticagentsin
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